Adimab Raises Third Round
Adimab Inc., a Lebanon, N.H.-based developer of a human antibody discovery platform in yeast, has raised an undisclosed amount of Series C funding. OrbiMed Advisors and Borealis Ventures were joined by return backers Polaris Venture Partners and SV Life Sciences. The company had previously raised over $9 million, since being launched by GlycoFi founder Tillman Gerngross.
20 November 2008•4 mins read
